SilcsBio and Dalriada Drug Discovery Launch Partnership to Create a Rapid Drug Discovery Service SuiteJune 11, 2020SilcsBio and Dalriada Drug Discovery Launch Partnership to Create a Rapid Drug Discovery Service Suite SilcsBio and Dalriada to tap areas of expertise in drug design and development to accelerate clients’ programs in development of therapeutic...
GEn1E Lifesciences, a Y Combinator-Backed Company, Granted Exclusive License for University of Maryland, Baltimore Drug Portfolio CompoundDecember 3, 2019GEn1E Lifesciences, a Y Combinator-Backed Company, Granted Exclusive License for University of Maryland, Baltimore Drug Portfolio Compound Tuesday, December 3, 2019 PALO ALTO, Calif. and BALTIMORE, Dec. 3, 2019 /PRNewswire/ — GEn1E...
New SILCS-MC Study Demonstrates Improved Performance with Machine Learning OptimizationMay 16, 2019 New SILCS-MC Study Demonstrates Improved Performance with Machine Learning Optimization May 16, 2019, Baltimore, MD – SilcsBio, a company that develops commercial software and related services for structure-based drug design, today...
SilcsBio, LLC Announces Release of CGenFF 2.3.0April 26, 2019Baltimore, MD, 26 April, 2019 In ongoing efforts to improve the coverage of the CGenFF program, version 2.3.0 of the CGenFF program improves support for a variety of molecules via explicit parametrization of the molecules outlined below and...
Sygnature Discovery announces collaboration with software firm SilcsBioApril 19, 2019
SilcsBio, LLC Receives NIH Funding to Expand Offerings in BiologicsApril 11, 2019FOR IMMEDIATE RELEASE: April 11, 2019 Ken Malone SilcsBio, LLC 410.929.2305 Ken.Malone@silcsbio.com SilcsBio, LLC Receives NIH Funding to Expand Offerings in Biologics Baltimore, Maryland: SilcsBio, LLC announced today a $225,000 award...